| Wed, 23 Sep 2026 | Czibere Akos | officer: Chief Medical Officer | S-Sale | 7,401 | $155.65K |
| Wed, 23 Sep 2026 | Czibere Akos | officer: Chief Medical Officer | S-Sale | 5,099 | $102.97K |
| Wed, 23 Sep 2026 | Czibere Akos | officer: Chief Medical Officer | M-Exempt | 12,500 | $61.88K |
| Mon, 20 Jul 2026 | Herrmann Ken | director | S-Sale | 1,350 | $33.16K |
| Mon, 20 Jul 2026 | Herrmann Ken | director | S-Sale | 3,506 | $86.12K |
| Mon, 20 Jul 2026 | Herrmann Ken | director | M-Exempt | 1,350 | $2.58K |
| Mon, 20 Jul 2026 | Herrmann Ken | director | M-Exempt | 3,506 | $280.48 |
| Fri, 17 Jul 2026 | Herrmann Ken | director | S-Sale | 3,065 | $77.26K |
| Fri, 17 Jul 2026 | Herrmann Ken | director | M-Exempt | 3,065 | $245.2 |
| Wed, 8 Jul 2026 | Czibere Akos | officer: Chief Medical Officer | S-Sale | 4,371 | $125.48K |
| Wed, 8 Jul 2026 | Czibere Akos | officer: Chief Medical Officer | S-Sale | 30,829 | $861.74K |
| Wed, 8 Jul 2026 | Czibere Akos | officer: Chief Medical Officer | S-Sale | 14,800 | $401.48K |
| Wed, 8 Jul 2026 | Czibere Akos | officer: Chief Medical Officer | M-Exempt | 50,000 | $247.5K |
| Wed, 8 Jul 2026 | Ron-Bigger Shulamit | officer: Chief Operating Officer | S-Sale | 4,200 | $120.74K |
| Wed, 8 Jul 2026 | Ron-Bigger Shulamit | officer: Chief Operating Officer | S-Sale | 30,000 | $838.14K |
| Wed, 8 Jul 2026 | Ron-Bigger Shulamit | officer: Chief Operating Officer | S-Sale | 15,800 | $428.68K |
| Wed, 8 Jul 2026 | Ron-Bigger Shulamit | officer: Chief Operating Officer | M-Exempt | 50,000 | $183K |
| Mon, 12 Jan 2026 | Foley Todd | director, 10 percent owner | C-Conversion | 2,688,270 | — |
| Mon, 12 Jan 2026 | GADICKE ANSBERT | 10 percent owner | C-Conversion | 5,914,197 | — |
| Mon, 12 Jan 2026 | GADICKE ANSBERT | 10 percent owner | C-Conversion | 1,577,119 | — |
| Mon, 12 Jan 2026 | GADICKE ANSBERT | 10 percent owner | P-Purchase | 1,112,777 | $20.03M |
| Mon, 12 Jan 2026 | GADICKE ANSBERT | 10 percent owner | C-Conversion | 1,314,262 | — |
| Mon, 12 Jan 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | 10 percent owner | P-Purchase | 1,112,777 | $20.03M |
| Mon, 12 Jan 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | 10 percent owner | C-Conversion | 1,314,262 | — |
| Mon, 12 Jan 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | 10 percent owner | C-Conversion | 5,914,197 | — |
| Mon, 12 Jan 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | 10 percent owner | C-Conversion | 1,577,119 | — |
| Mon, 12 Jan 2026 | Foley Todd | director, 10 percent owner | C-Conversion | 716,872 | — |
| Mon, 12 Jan 2026 | Foley Todd | director, 10 percent owner | C-Conversion | 597,391 | — |
| Mon, 12 Jan 2026 | Foley Todd | director, 10 percent owner | P-Purchase | 232,870 | $4.19M |
| Mon, 12 Jan 2026 | VIDA VENTURES II-A, LLC | 10 percent owner | P-Purchase | 22,545 | $405.81K |
| Mon, 12 Jan 2026 | VIDA VENTURES II-A, LLC | 10 percent owner | C-Conversion | 4,859,370 | — |
| Mon, 12 Jan 2026 | NODELMAN OLEG | director | P-Purchase | 144,443 | $2.6M |
| Mon, 12 Jan 2026 | NODELMAN OLEG | director | C-Conversion | 2,270,879 | — |
| Mon, 12 Jan 2026 | NODELMAN OLEG | director | C-Conversion | 202,862 | — |
| Mon, 12 Jan 2026 | NODELMAN OLEG | director | C-Conversion | 128,506 | — |
| Mon, 12 Jan 2026 | NODELMAN OLEG | director | P-Purchase | 2,077,779 | $37.4M |
| Mon, 12 Jan 2026 | Kim Helen Susan | director, 10 percent owner | P-Purchase | 812,455 | $14.62M |
| Mon, 12 Jan 2026 | Kim Helen Susan | director, 10 percent owner | C-Conversion | 134,842 | — |
| Mon, 12 Jan 2026 | Kim Helen Susan | director, 10 percent owner | P-Purchase | 22,545 | $405.81K |
| Mon, 12 Jan 2026 | Kim Helen Susan | director, 10 percent owner | C-Conversion | 4,859,370 | — |
| Mon, 12 Jan 2026 | Segal Lloyd Mitchell | director | C-Conversion | 19,631 | — |
| Mon, 12 Jan 2026 | VIDA VENTURES II-A, LLC | 10 percent owner | P-Purchase | 812,455 | $14.62M |
| Mon, 12 Jan 2026 | VIDA VENTURES II-A, LLC | 10 percent owner | C-Conversion | 134,842 | — |
